CRK SH3N Domain Diminishes Cell Invasiveness of Non-Small Cell Lung Cancer

Genes and Cancer

Volumn 4, Issue 7-8, 2013, Pages 315-324

  Pezeshkpour, Gholam H ^a   Moatamed, Farhad ^a   Lewis, Michael ^a   Hoang, Bao ^b   Rettig, Matthew ^b,c,d   Mortazavi, Fariborz ^b,c,d  

^a West Los Angeles VA ^*  (United States)

^b Division of Hematology Oncology   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

c Crk; cell adhesion; cell invasion; lung cancer; protein domains; signal transduction

Indexed keywords

CRK LIKE PROTEIN; DOCKING PROTEIN; PROTEIN CRK II; PROTEIN DOCK180; PROTEIN SH3; PROTEIN SH3N; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL ADHESION; CELL DIFFERENTIATION; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; GENETIC TRANSFECTION; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

EID: 84887471918     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601913497573     Document Type: Article

References (28)

1. Mayer BJ,Hamaguchi M,Hanafusa H.A novel viral oncogene with structural similarity to phospholipase C.Nature. 1988;332 (6161): 272-5.
2. Mayer BJ,Hamaguchi M,Hanafusa H.Characterization of p47gag-crk, a novel oncogene product with sequence similarity to a putative modulatory domain of protein-tyrosine kinases and phospholipase C.Cold Spring Harb Symp Quant Biol. 1988;53 (Pt 2): 907-14.
3. Birge RB,Kalodimos C,Inagaki F,Tanaka S.Crk and CrkL adaptor proteins: networks for physiological and pathological signaling.Cell Commun Signal. 2009;7:13.
4. Feller SM.Crk family adaptors-signalling complex formation and biological roles.Oncogene. 2001;20 (44): 6348-71.
5. Miller CT,Chen G,Gharib TG,et al.Increased C-CRK proto-oncogene expression is associated with an aggressive phenotype in lung adenocarcinomas.Oncogene. 2003;22 (39): 7950-7.
6. Takino T,Nakada M,Miyamori H,Yamashita J,Yamada KM,Sato H.CrkI adapter protein modulates cell migration and invasion in glioblastoma.Cancer Res. 2003;63 (9): 2335-7.
7. Nishihara H,Tanaka S,Tsuda M,et al.Molecular and immunohistochemical analysis of signaling adaptor protein Crk in human cancers.Cancer Lett. 2002;180 (1): 55-61.
8. Ota S,Kizaka-Kondoh S,Hashimoto Y,et al.Constitutive association of EGF receptor with the CrkII-23 mutant that inhibits transformation of NRK cells by EGF and TGF-beta.Cell Signal. 1998;10 (4): 283-90.
9. Ishiki M,Sasaoka T,Ishihara H,et al.Evidence for functional roles of Crk-II in insulin and epidermal growth factor signaling in Rat-1 fibroblasts overexpressing insulin receptors.Endocrinology. 1997;138 (11): 4950-8.
10. Garcia-Guzman M,Dolfi F,Zeh K,Vuori K.Met-induced JNK activation is mediated by the adapter protein Crk and correlates with the Gab1-Crk signaling complex formation.Oncogene. 1999;18 (54): 7775-86.
11. Lamorte L,Royal I,Naujokas M,Park M.Crk adapter proteins promote an epithelial-mesenchymal-like transition and are required for HGF-mediated cell spreading and breakdown of epithelial adherens junctions.Mol Biol Cell. 2002;13 (5): 1449-61.
12. Lamorte L,Rodrigues S,Naujokas M,Park M.Crk synergizes with epidermal growth factor for epithelial invasion and morphogenesis and is required for the met morphogenic program.J Biol Chem. 2002;277 (40): 37904-11.
13. Smith JJ,Evans EK,Murakami M,et al.Wee1-regulated apoptosis mediated by the crk adaptor protein in Xenopus egg extracts.J Cell Biol. 2000;151 (7): 1391-400.
14. Takino T,Tamura M,Miyamori H,et al.Tyrosine phosphorylation of the CrkII adaptor protein modulates cell migration.J Cell Sci. 2003;116 (Pt 15): 3145-55.
15. Cho SY,Klemke RL.Extracellular-regulated kinase activation and CAS/Crk coupling regulate cell migration and suppress apoptosis during invasion of the extracellular matrix.J Cell Biol. 2000;149 (1): 223-36.
16. Kain KH,Gooch S,Klemke RL.Cytoplasmic c-Abl provides a molecular "Rheostat" controlling carcinoma cell survival and invasion.Oncogene. 2003;22 (38): 6071-80.
17. Knaus UG,Bokoch GM.The p21Rac/Cdc42-activated kinases (PAKs).Int J Biochem Cell Biol. 1998;30 (8): 857-62.
18. Manser E,Leung T,Salihuddin H,Zhao ZS,Lim L.A brain serine/threonine protein kinase activated by Cdc42 and Rac1.Nature. 1994;367 (6458): 40-6.
19. Parrini MC,Lei M,Harrison SC,Mayer BJ.Pak1 kinase homodimers are autoinhibited in trans and dissociated upon activation by Cdc42 and Rac1.Mol Cell. 2002;9 (1): 73-83.
20. Stockton RA,Schaefer E,Schwartz MA.p21-activated kinase regulates endothelial permeability through modulation of contractility.J Biol Chem. 2004;279 (45): 46621-30.
21. Mortazavi F,Dubinett S,Rettig M.c-Crk proto-oncogene contributes to transcriptional repression of p120-catenin in non-small cell lung cancer cells.Clin Exp Metastasis. 2011;28 (4): 391-404.
22. Uemura N,Salgia R,Li JL,Pisick E,Sattler M,Griffin JD.The BCR/ABL oncogene alters interaction of the adapter proteins CRKL and CRK with cellular proteins.Leukemia. 1997;11 (3): 376-85.
23. Mizutani T,Kondo T,Darmanin S,et al.A novel FRET-based biosensor for the measurement of BCR-ABL activity and its response to drugs in living cells.Clin Cancer Res. 2010;16 (15): 3964-75.
24. Tunceroglu A,Matsuda M,Birge RB.Real-time fluorescent resonance energy transfer analysis to monitor drug resistance in chronic myelogenous leukemia.Mol Cancer Ther. 2010;9 (11): 3065-73.
25. Liu BA,Jablonowski K,Raina M,Arce M,Pawson T,Nash PD.The human and mouse complement of SH2 domain proteins-establishing the boundaries of phosphotyrosine signaling.Mol Cell. 2006;22 (6): 851-68.
26. Harkiolaki M,Lewitzky M,Gilbert RJ,et al.Structural basis for SH3 domain-mediated high-affinity binding between Mona/Gads and SLP-76.EMBO J. 2003;22 (11): 2571-82.
27. van den BA,Dowdy SF.Protein transduction domain delivery of therapeutic macromolecules.Curr Opin Biotechnol. 2011;22 (6): 888-93.
28. Mortazavi F,An J,Dubinett S,Rettig M.p120-catenin is transcriptionally downregulated by FOXC2 in non-small cell lung cancer cells.Mol Cancer Res. 2010;8 (5): 762-74.